What Does Nutriband (NTRB) Do? – Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters Overview
Nutriband (NTRB) is a biotech company that operates both abuse-deterrent transdermal pharmaceuticals and a manufacturing business. While revenue is driven by the manufacturing segment, the company's outlook hinges on the regulatory process and commercialization readiness of its lead candidate, so related stocks and development risk should be reviewed together.
SubscribeNutriband focuses its business on transdermal formulations that deliver drugs through the skin, with an emphasis on developing technologies that reduce the risk of prescription drug abuse and accidental exposure. Its structure is distinctive in that it runs research and development alongside a manufacturing operation.
Its core business is the development of transdermal drug candidates that apply Aversa technology. At the same time, it operates medical device and consumer health product manufacturing to partially offset the uncertainty of the development stage while accumulating experience in product production and distribution.
💰 How does Nutriband make money?
| Business Segment | Revenue Weight | Description |
|---|---|---|
| Transdermal Pharmaceutical Development | Core Growth Driver | Research and commercialization preparation for prescription drug candidates that apply abuse-deterrent technology. |
| Medical Device and Consumer Health Manufacturing | Supplementary Business | Sales and distribution expansion of manufactured products such as kinesiology tape to support the revenue base. |
Nutriband's revenue mix is shaped in the short term by orders and distribution expansion in the manufacturing business, while long-term value may be more closely tied to regulatory progress and commercialization potential of its transdermal candidates. The manufacturing business supports production experience and counterparty expansion, but development costs and approval timelines for drug candidates remain variables that affect profitability. As a result, it is important to examine revenue stability, R&D burden, and candidate progress as separate factors.
Market cap stands at $73.9M and the employee count has not been disclosed.
Nutriband is a publicly listed biotech company that is concentrated in the niche areas of transdermal drug delivery and abuse deterrence while also running a manufacturing operation. Corporate value can be sensitive to the clinical and regulatory progress of its candidates, recurring orders from the manufacturing business, and funding conditions. For this reason, rather than drawing simple comparisons with companies that hold broad pharmaceutical portfolios, it is necessary to review both the commercialization potential of a specific technology and the durability of operations.
Nutriband Outlook and Stock Price Trends
In the short term, the order flow of manufactured products and expansion of distribution channels are variables that can lift revenue visibility. Over the medium to long term, study results, regulatory submissions, and production system setup for the Aversa fentanyl candidate may serve as the core growth drivers. However, transdermal drug development involves multiple interlocking stages—including interpretation of research data, regulatory decisions, production preparation, and distribution partnerships—which can lead to schedule delays or additional funding needs. It should also be kept in mind that growth in the manufacturing business alone may not fully offset development risk.
⚔️ Nutriband's Core Strengths and Risks
Differentiated development axes in transdermal formulation and abuse-deterrent technology, along with a complementary revenue structure from the manufacturing business, are strengths. On the other hand, regulatory outcomes for the lead candidate and funding conditions are key uncertainties.
💪 Core Strengths
⚠️ Core Risks
🔄 Nutriband Competitors and Related Stocks (Beneficiaries)
Because Nutriband is concentrated in transdermal patches and abuse-deterrent technology, direct competitors within the same product group are limited among the candidates provided. As related stocks, other names in the healthcare biotech sector such as NNVC, GRCE, and LTRN can be viewed as comparison points. Since each of these names covers a different business area, the development stage and funding conditions of individual candidates should be compared separately from those of Nutriband.
✅ Investor Checkpoints for Nutriband
When reviewing Nutriband, an approach is needed that does not evaluate the value of the transdermal drug candidates and the revenue base of the manufacturing business by the same standard. Progress in R&D can serve as an indicator of long-term potential, while the manufacturing business can serve as an indicator of short-term operating durability.
| Checkpoint | What to Verify | Current Status |
|---|---|---|
| 🧪 Development Progress | Confirm the flow of regulatory submissions and study result releases for the lead candidate. | Under Observation |
| 💵 Manufacturing Revenue | Examine how order expansion in manufacturing and consumer health products affects cash flow. | To Be Confirmed |
| ⚖️ Funding Conditions | Review capital sourcing and spending changes needed for clinical and commercialization preparation. | Subject to Change |
If the lead candidate fails to clear regulatory procedures or its timeline is delayed, expectations regarding development value could weaken. In addition, if manufacturing orders weaken or development costs increase, the burden on operating capital can grow, so research outcomes and financial conditions should be reviewed together.
Nutriband is a company that combines the development potential of abuse-deterrent transdermal pharmaceuticals with a complementary revenue base from manufacturing. However, because regulatory progress on the lead candidate and funding conditions can determine long-term performance, it is necessary to compare manufacturing revenue trends and development schedule changes from multiple angles.
1-Year Price Performance
Analyst Consensus
52-Week Price Range⚔️ Nutriband's Core Strengths and Risks
Differentiated development axes in transdermal formulation and abuse-deterrent technology, along with a complementary revenue structure from the manufacturing business, are strengths. On the other hand, regulatory outcomes for the lead candidate and funding conditions are key uncertainties.
💪 Core Strengths
⚠️ Core Risks
🔄 Nutriband Competitors and Related Stocks (Beneficiaries)
Because Nutriband is concentrated in transdermal patches and abuse-deterrent technology, direct competitors within the same product group are limited among the candidates provided. As related stocks, other names in the healthcare biotech sector such as NNVC, GRCE, and LTRN can be viewed as comparison points. Since each of these names covers a different business area, the development stage and funding conditions of individual candidates should be compared separately from those of Nutriband.
Related stocks (beneficiaries)| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
 NNVC | NanoViricides Inc | $1.02 | -1.9% | $26.0M | - | 2.4 | -89.97% | - |
 GRCE | Grace Therapeutics Inc | $2.26 | +5.6% | $47.5M | - | 0.8 | -36.19% | - |
 LTRN | Lantern Pharma Inc | $1.76 | -0.6% | $22.5M | - | - | -400.92% | - |
✅ Investor Checkpoints for Nutriband
When reviewing Nutriband, an approach is needed that does not evaluate the value of the transdermal drug candidates and the revenue base of the manufacturing business by the same standard. Progress in R&D can serve as an indicator of long-term potential, while the manufacturing business can serve as an indicator of short-term operating durability.
| Checkpoint | What to Verify | Current Status |
|---|---|---|
| 🧪 Development Progress | Confirm the flow of regulatory submissions and study result releases for the lead candidate. | Under Observation |
| 💵 Manufacturing Revenue | Examine how order expansion in manufacturing and consumer health products affects cash flow. | To Be Confirmed |
| ⚖️ Funding Conditions | Review capital sourcing and spending changes needed for clinical and commercialization preparation. | Subject to Change |
If the lead candidate fails to clear regulatory procedures or its timeline is delayed, expectations regarding development value could weaken. In addition, if manufacturing orders weaken or development costs increase, the burden on operating capital can grow, so research outcomes and financial conditions should be reviewed together.
Nutriband is a company that combines the development potential of abuse-deterrent transdermal pharmaceuticals with a complementary revenue base from manufacturing. However, because regulatory progress on the lead candidate and funding conditions can determine long-term performance, it is necessary to compare manufacturing revenue trends and development schedule changes from multiple angles.
Subscribe Today's 5 AI picks, all free